www.kience.com Open in urlscan Pro
104.21.4.67  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Home
 * Solutions
   
   CANCER PREVENTION
   
    * * Venient Cx Health Check Comprehensive
   
   INDIVIDUAL HEALTH TESTS
   
   
   IRON FUNCTION
   
    * Venient Cx Iron Function Comprehensive
   
   
   CARDIOVASCULAR FUNCTION
   
    * Venient Cx Cardiovascular Function Comprehensive
   
   
   ENDOCRINE FUNCTION
   
   
   PANCREATIC ENDONCRINE FUNCTION
   
    * Venient Cx Pancreatic Endocrine Function Comprehensive
   
   
   THYROID FUNCTION
   
    * Venient Cx Thyroid Function Comprehensive
   
   
   PARATHYROID FUNCTION
   
    * Venient Cx Parathyroid Function Comprehensive
   
   
   LIVER & BILE FUNCTION
   
    * Venient Cx Hepatic Function Comprehensive
   
   
   GENITOURINARY SYSTEM
   
   
   RENAL FUNCTION
   
    * Venient Cx Renal Function Comprehensive
   
   
   HYDROELECTROLYTIC METABOLISM
   
    * Venient Cx Hydroelectrolytic Metabolism Comprehensive
   
   
   PROSTATE FUNCTION
   
    * Venient Cx Prostate Function Comprehensive
   
   
   INFLAMMATORY RESPONSE
   
    * Venient Cx Inflammatory Response Basic
   
   CANCER SCREENING
   
    * * Venient Sx MCED (Multi-Cancer Early Detection Test)
      * Venient Sx Breast
      * Venient Sx Colon
      * Venient Sx Liver Basic (HCC)
      * Venient Sx Ovarian
      * Venient Sx Prostate
   
   CANCER CONFIRMATION DIAGNOSIS
   
    * * Venient CDx Lung

 * Our approach
 * About us
 * FAQ
 * Contact


THE NEW GOLD STANDARD FOR CANCER DETECTION AND PREVENTION

Discover our disruptive Venient Sx MCED (Multi-Cancer Early Detection) test as
the best way to detect and prevent more than 50 different types of cancers.

Our solutions are part of an ambitious portfolio of 106 diagnostic tests and are
currently undergoing the AMA validation to obtain PLA/CPT codes towards Medicare
reimbursement.

Download MCED ESMO Poster


Discover our disruptive Venient Sx MCED (Multi-Cancer Early Detection) test as
the best way to detect and prevent more than 50 different types of cancers.

Our solutions are part of an ambitious portfolio of 106 diagnostic tests and are
currently undergoing the AMA validation to obtain PLA/CPT codes towards Medicare
reimbursement.

Download MCED ESMO Poster
Discover
our approach


OUR REVOLUTIONARY APPROACH

Thinking ahead of the curve and challenging the status quo is part of our DNA.
We are driven forward by our ambition to live in a reality with no more cancer
deaths.

We cannot cure cancer, but we can prevent and detect multiple types of cancer
―even in the early stages, when treatment is more likely to be succesful―
improving life expectancy and as the the best way to avoid developing them in
the future, thanks to personalized advice and recommendations, based on their
laboratory results and lifestyle habits.

Click here
to know more


SCIENCE AND TECHNOLOGY FOR AN INTEGRATIVE VISION

Our unique methodology masterfully integrates tools and knowledge from both
science and technology in order to detect cancer in a less invasive, more
accurate way.

Continue reading

We firmly believe that abiding by scientific principles and methods, and relying
on solid evidence and data are fundamental to achieve the highest quality cancer
testing solutions yet.

Integrating technological knowledge into the equation creates space for
innovation and development of our own software and equipment, allowing our
solutions to evolve and adapt, and also leveraging data to maximize the accuracy
and efficiency of our diagnostics.

An integrative methodological approach with an outstanding team of professionals
is the key to Kience's success.

These highly capable professionals are also accompanied by independent advisors
with the relevant credentials and scientific backgrounds.


KEY PUBLICATIONS

 * Diagnostic accuracy of the CxPREVENTIVE™ Breast model for early detection of
   breast cancer (rebranded as Venient Sx Breast).
 * Diagnostic accuracy of the CxPREVENTIVE™ Colon model for early detection of
   colorectal cancer (rebranded as Venient Sx Colon).





REVOLUTIONIZING CANCER DIAGNOSIS THROUGH INNOVATIVE AI TESTING SOLUTIONS.
SAVING MILLIONS OF LIVES.




CANCER SCREENING TESTS

Disruptive and non-invasive screening tests for the early detection of cancer in
asymptomatic patients, even in early stages, before symptoms appear and when
treatment is most likely to be successful.

All Venient Sx screening tests are exclusively based on routine blood and urine
tests, which powered by our own Machine Learning algorithms (ML), provide
unprecedented rates of accuracy.

Previous
Venient Sx


MCED

Disruptive and non-invasive screening test for Multi-Cancer Early Detection
(MCED), based on a routine blood and urine analysis and powered by both public
and machine learning (ML) proprietary algorithms. It is able to accurately
detect up to 42 solid and 5 hematological tumors ―accounting for 95.2 percent of
new cancer cases types worldwide―, even in early stages, before symptoms appear
and when treatment is most likely to be successful.

Learn more

DISCOVER ALL OUR CANCER SCREENING PORTFOLIO

 * Venient Sx Breast
 * Venient Sx Colon
 * Venient Sx Liver Basic (HCC)
 * Venient Sx Ovarian
 * Venient Sx Prostate

Venient Sx


COLON

Disruptive and non-invasive screening test for colorectal cancer (CRC) early
detection, based on a routine blood and urine analysis and powered by both
public and machine learning (ML) proprietary algorithms. It is able to
accurately detect CRC, polyps and inflammatory bowel disease (IBD) ―ulcerative
colitis and Chron's disease―, even in early stages, before symptoms appear and
when treatment is most likely to be successful.

Key Publication: Diagnostic accuracy of the CxPREVENTIVE™ Colon model for early
detection of colorectal cancer (rebranded as Venient Sx Colon).

Learn more

DISCOVER ALL OUR CANCER SCREENING PORTFOLIO

 * Venient Sx MCED (Multi-Cancer Early Detection Test)
 * Venient Sx Breast
 * Venient Sx Liver Basic (HCC)
 * Venient Sx Ovarian
 * Venient Sx Prostate

Venient Sx


BREAST

Disruptive and non-invasive screening test for breast cancer early detection,
based on a routine blood and urine analysis and powered by both public and
machine learning (ML) proprietary algorithms. It is able to accurately detect
breast cancer even in early stages, before symptoms appear and when treatment is
most likely to be successful.

Learn more

DISCOVER ALL OUR CANCER SCREENING PORTFOLIO

 * Venient Sx MCED (Multi-Cancer Early Detection Test)
 * Venient Sx Colon
 * Venient Sx Liver Basic (HCC)
 * Venient Sx Ovarian
 * Venient Sx Prostate

Next


CANCER PREVENTION TESTS

Disruptive and non-invasive health tests focused on the detection and prevention
of the most prevalent non-malignant diseases, many of them precursors of cancer.
They provide exhaustive information about the main functions, systems and
metabolisms of the body.

Venient Cx


HEALTH CHECK COMPREHENSIVE

Disruptive and non-invasive test for a comprehensive assessment of major body
functions, systems and metabolisms as a whole, given that many diseases or
pathologies have a multifacetic component that makes them difficult to diagnose.

Learn more


WE EXIST TO SAVE MILLIONS OF LIVES BY REVOLUTIONIZING THE WAY CANCER IS DETECTED
AND PREVENTED


WE BELIEVE THAT INNOVATION IS THE MOST POWERFUL FORCE FOR CHANGE

and we are committed to continually improving, innovating and combining
scientific rigor with an open-minded approach, to offer state-of-the-art,
effective tools capable of rewriting how cancer is faced.

By keeping an optimistic and groundbreaking perspective of our world and
trusting each other throughout the process, we discover all that we can achieve
together.


GET THE LATEST NEWS ABOUT OUR JOURNEY

Sign up
for our newsletter
 * 
 * 
   

Sections

 * Our approach
 * About us
 * Contact

Legal

   
 * Legal Notice and Privacy Policy
 * HIPAA Notice
 * Quality and Regulatory Policy
 * Advertising Policy
 * Cookies Policy
   

Address:
1000 N West St, Suite 1200
Wilmington, DE 19801-1058
US
Email:
hello@kience.com

Copyright © 2024 Kience Inc.. All rights reserved.